{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-052068","form_type":"8-K","ticker":"INFU","cik":"0001337013","company_name":"InfuSystem Holdings, Inc","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.184377+00:00","generated_at":"2026-05-16T20:11:49.762568+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"InfuSystem TTM revenue $141.1M, AEBITDA $30.2M; guides 6-8% FY2025 growth","bullets":["TTM revenue through Sep 30, 2025: $141.1M; estimated 2025 revenue grows 6-8% over 2024's $134.9M.","Adjusted EBITDA TTM $30.2M (21.4% margin); estimated 2025 AEBITDA margin >20% of revenue.","Patient Services net revenue TTM $85.4M; Device Solutions $55.7M; gross margin 55.4%.","Stock repurchases of $9.7M under $20M program through Sep 30, 2025; program expires Jun 30, 2026.","ERP upgrade investment estimated $2.6M in 2025 ($3.3M cumulative); expected completion Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-052068","json":"https://secwatch.observer/filing/0001628280-25-052068.json","markdown":"https://secwatch.observer/filing/0001628280-25-052068.md","text":"https://secwatch.observer/filing/0001628280-25-052068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1337013/000162828025052068/0001628280-25-052068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1337013/000162828025052068/infu-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:11:49.762568+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}